TITLE

Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis

AUTHOR(S)
Pabst, T.; Eyholzer, M.; Fos, J.; Mueller, B. U.
PUB. DATE
April 2009
SOURCE
British Journal of Cancer;4/21/2009, Vol. 100 Issue 8, p1343
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
CCAAT/enhancer binding protein alpha (CEBPA) mutations in AML are associated with favourable prognosis and are divided into N- and C-terminal mutations. The majority of AML patients have both types of mutations. We assessed the prognostic significance of single (n=7) and double (n=12) CEBPA mutations among 224 AML patients. Double CEBPA mutations conferred a decisively favourable overall (P=0.006) and disease-free survival (P=0.013). However, clinical outcome of patients with single CEBPA mutations was not different from CEBPA wild-type patients. In a multivariable analysis, only double – but not single – CEBPA mutations were identified as independent prognostic factors. These findings indicate heterogeneity within AML patients with CEBPA mutations.British Journal of Cancer (2009) 100, 1343–1346; doi:10.1038/sj.bjc.6604977 www.bjcancer.com Published online 10 March 2009
ACCESSION #
37591425

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics